probucol has been researched along with Atherogenesis in 57 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of probucol, aspirin and atorvastatin (PAS) combination therapy upon atherosclerosis." | 9.14 | [Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis]. ( Geng, L; Li, ZX; Meng, XP; Wang, SX; Yin, CY; Zhang, JC, 2009) |
| "We have investigated the possible effects and mechanism of atorvastatin, a statin, and/or probucol, a powerful antioxidant used to lower cholesterol before 1995, on the atherosclerosis development." | 7.91 | Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. ( Guo, X; Li, X; Wang, L; Wang, P; Xia, X, 2019) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 7.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 7.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Activation of Na(+)/H(+) exchanger 1 (NHE1) by lipopolysaccharide (LPS) via Ca(2+)/calpain is responsible in vascular smooth muscle cell (VSMC) apoptosis and to the process of atherosclerosis." | 7.80 | Probucol via inhibition of NHE1 attenuates LPS-accelerated atherosclerosis and promotes plaque stability in vivo. ( Chen, S; Feng, JD; Li, JF; Liu, XX; Zhang, MY, 2014) |
| "This study aimed to study the combined effect of rosuvastatin and probucol on atherosclerosis (AS) in rats." | 7.80 | Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats. ( Chen, X; Chen, Z; Li, S; Wang, X; Zhao, W, 2014) |
| "This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima." | 7.79 | Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013) |
| "Probucol is known to reduce the development of atherosclerotic lesions, but its impact on vascular remodeling associated with de novo atherosclerosis is incompletely understood." | 7.77 | Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study. ( Guo, Y; Li, TT; Peng, J; Tian, HB; Xie, Y; Zhang, JN; Zhang, Y, 2011) |
| "Probucol alleviated atherosclerosis by improving HDL function." | 7.77 | Probucol alleviates atherosclerosis and improves high density lipoprotein function. ( Guo, ZG; Lai, WY; Li, C; Tu, Y; Wang, ZK; Zhong, JK, 2011) |
| "Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] was withdrawn from the United States market because it failed to inhibit atherosclerosis in human femoral arteries, yet the drug was shown subsequently to inhibit atherosclerosis in human carotid arteries, and probucol monosuccinate ester is presently being tested in a phase III clinical trial as an antiatherosclerotic compound based on its anti-inflammatory properties." | 7.74 | Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. ( Beck, K; Choy, K; Di Girolamo, N; Hanratty, CG; Hou, JY; Stocker, R; Ward, MR; Wu, BJ, 2007) |
| "Probucol affects atherosclerosis in apoE(-/-) mice independent of the accumulation of arterial lipid oxidation products, thereby dissociating the 2 processes." | 7.73 | Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. ( Beck, K; Choy, K; Croft, KD; Hou, JY; Leichtweis, SB; Mori, TA; Png, FY; Stocker, R; Thomas, SR; Wu, BJ, 2005) |
| " The aims of the present study were to investigate whether (a) dietary phytosterols reduce probucol-induced atherogenesis and (b) beneficial interactions exist between these agents." | 7.73 | Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. ( Moghadasian, MH, 2006) |
| "In this study, we integrated two randomized control trials, PROSPECTIVE and IMPACT, to address the effect of probucol on cerebrocardiovascular events and carotid intima-media thickness (IMT) in Japanese, Korean, and Chinese patients with coronary artery disease (CAD)." | 5.51 | Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. ( Arai, H; Bujo, H; Fukushima, M; Ge, J; Ishibashi, T; Kagimura, T; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Kita, T; Masuda, D; Matsuzawa, Y; Nakagawa, S; Oh, BH; Park, JE; Saito, Y; Sung, J; Tanabe, K; Yamashita, S, 2022) |
| "To investigate the effects of probucol, aspirin and atorvastatin (PAS) combination therapy upon atherosclerosis." | 5.14 | [Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis]. ( Geng, L; Li, ZX; Meng, XP; Wang, SX; Yin, CY; Zhang, JC, 2009) |
| "Probucol is a diphenolic compound with anti-oxidant and anti-inflammatory properties that reduces atherosclerosis and restenosis." | 4.84 | Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. ( Hime, N; Stocker, R; Tanous, D, 2008) |
| "We have investigated the possible effects and mechanism of atorvastatin, a statin, and/or probucol, a powerful antioxidant used to lower cholesterol before 1995, on the atherosclerosis development." | 3.91 | Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. ( Guo, X; Li, X; Wang, L; Wang, P; Xia, X, 2019) |
| "Oxidised low density lipoprotein (LDL) was considered to be important in the pathogenesis of atherosclerosis, but the large clinical trials of antioxidants, including the first one using probucol (the PQRST Trial), failed to show benefit and have cast doubt on the importance of oxidised LDL." | 3.88 | Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed. ( Ahmad, F; Leake, DS, 2018) |
| "We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice." | 3.88 | HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution. ( Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018) |
| " Based on previous studies demonstrating the important antioxidant and anti-hyperlipidemic effect of morpholine and 1,4-benzo(x/thi)azine derivatives (A-E), we hereby present the design, synthesis and pharmacological evaluation of novel dual-acting molecules as a therapeutic approach for atherosclerosis." | 3.85 | Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity. ( Katselou, MG; Kourounakis, AP; Matralis, AN, 2017) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 3.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 3.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Activation of Na(+)/H(+) exchanger 1 (NHE1) by lipopolysaccharide (LPS) via Ca(2+)/calpain is responsible in vascular smooth muscle cell (VSMC) apoptosis and to the process of atherosclerosis." | 3.80 | Probucol via inhibition of NHE1 attenuates LPS-accelerated atherosclerosis and promotes plaque stability in vivo. ( Chen, S; Feng, JD; Li, JF; Liu, XX; Zhang, MY, 2014) |
| " In this study of atherosclerosis in rabbits, we examined the effect of probucol, a lipid-lowering drug with potent antioxidative effects, added to treatment with atorvastatin." | 3.80 | Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. ( Imaizumi, A; Itabe, H; Keyamura, Y; Kohashi, M; Koyama, T; Nagano, C; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2014) |
| "This study aimed to study the combined effect of rosuvastatin and probucol on atherosclerosis (AS) in rats." | 3.80 | Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats. ( Chen, X; Chen, Z; Li, S; Wang, X; Zhao, W, 2014) |
| "This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima." | 3.79 | Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013) |
| " Probucol is a compound that reduces HDL-C levels but also reduces atherosclerosis in animal models and xanthomas in humans." | 3.77 | Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. ( Billheimer, JT; Komaru, Y; Li, X; Rader, DJ; Tanigawa, H; Yamamoto, S, 2011) |
| "Probucol is known to reduce the development of atherosclerotic lesions, but its impact on vascular remodeling associated with de novo atherosclerosis is incompletely understood." | 3.77 | Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study. ( Guo, Y; Li, TT; Peng, J; Tian, HB; Xie, Y; Zhang, JN; Zhang, Y, 2011) |
| "Probucol alleviated atherosclerosis by improving HDL function." | 3.77 | Probucol alleviates atherosclerosis and improves high density lipoprotein function. ( Guo, ZG; Lai, WY; Li, C; Tu, Y; Wang, ZK; Zhong, JK, 2011) |
| "Probucol treatment paradoxically reduced plasma cholesterol levels, increased plasma cytokine levels and atherogenesis in apo E-KO mice." | 3.75 | Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver. ( Azordegan, N; Le, K; Moghadasian, MH; Othman, RA; Xu, Z; Zhao, Z, 2009) |
| "Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] was withdrawn from the United States market because it failed to inhibit atherosclerosis in human femoral arteries, yet the drug was shown subsequently to inhibit atherosclerosis in human carotid arteries, and probucol monosuccinate ester is presently being tested in a phase III clinical trial as an antiatherosclerotic compound based on its anti-inflammatory properties." | 3.74 | Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. ( Beck, K; Choy, K; Di Girolamo, N; Hanratty, CG; Hou, JY; Stocker, R; Ward, MR; Wu, BJ, 2007) |
| "Cilostazol, an antiplatelet drug, and probucol, a cholesterol-lowering drug, are reported to ameliorate atherosclerosis in animal models." | 3.74 | Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. ( Kotosai, K; Mitani, K; Miyakoda, G; Nozako, M; Yabuuchi, Y; Yoshikawa, T, 2008) |
| "Probucol affects atherosclerosis in apoE(-/-) mice independent of the accumulation of arterial lipid oxidation products, thereby dissociating the 2 processes." | 3.73 | Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. ( Beck, K; Choy, K; Croft, KD; Hou, JY; Leichtweis, SB; Mori, TA; Png, FY; Stocker, R; Thomas, SR; Wu, BJ, 2005) |
| " A striking exception is probucol, which retards atherosclerosis in carotid arteries and restenosis of coronary arteries after angioplasty." | 3.73 | Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. ( Adams, MR; Beck, K; Choy, K; Croft, KD; Kathir, K; Lau, AK; Li, C; Mori, TA; Stocker, R; Tanous, D; Witting, PK; Wu, BJ, 2006) |
| " The aims of the present study were to investigate whether (a) dietary phytosterols reduce probucol-induced atherogenesis and (b) beneficial interactions exist between these agents." | 3.73 | Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. ( Moghadasian, MH, 2006) |
| "Atherosclerosis is more likely to occur in people with several risk factors, such as diabetes, hypertension, hyperlipidaemia, and smoking." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| " This may be related to factors such as the population and the dosage and time of taking natural products involved in different studies." | 2.72 | Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. ( Chen, W; Feng, X; Li, L; Xu, S; Zhang, L; Zhang, S, 2021) |
| "Atherosclerosis is now well recognised as a chronic inflammatory process which may ultimately lead to myocardial infarction, stroke and peripheral vascular disease." | 2.44 | Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? ( Preiss, DJ; Sattar, N, 2007) |
| " AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants." | 2.44 | AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. ( Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007) |
| "Probucol has reduced postpercutaneous coronary intervention (PCI)-restenosis and progression of carotid atherosclerosis in clinical trials." | 2.43 | Antioxidants: the good, the bad and the ugly. ( Tardif, JC, 2006) |
| "Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16." | 1.62 | Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. ( Inui, H; Kanno, K; Katayama, Y; Koseki, M; Masuda, D; Nishida, M; Ohama, T; Okada, T; Saga, A; Sakata, Y; Sumida, M; Yamashita, S, 2021) |
| "Because atherosclerosis is an inflammatory process involving a series of pathological events such as dyslipidemia, oxidative stress, and blood clotting mechanisms, we hereby report the synthesis and evaluation of novel compounds in which antioxidant, anti-inflammatory, and squalene synthase (SQS) inhibitory/hypolipidemic activities are combined in simple molecules through design." | 1.40 | Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity. ( Kourounakis, AP; Matralis, AN, 2014) |
| "Atherosclerosis is a multifactorial disease with several mechanisms participating in its manifestation." | 1.37 | Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. ( Katselou, MG; Kourounakis, AP; Matralis, AN; Nikitakis, A, 2011) |
| "Ellagic acid is a phenolic compound present in fruits and nuts, and has been found to have antioxidative property." | 1.33 | Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. ( Chang, WC; Chiang, SY; Wu, CH; Yu, YM, 2005) |
| "Probucol did not increase human SR-BI protein in the liver of transgenic mice carrying the entire human SR-BI genome." | 1.33 | Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. ( Hirano, K; Ikegami, C; Koseki, M; Maruyama, T; Masuda, D; Matsuura, F; Nakagawa-Toyama, Y; Shimomura, I; Tsujii, K; Ueda, Y; Yamashita, S; Zhang, Z, 2005) |
| "Probucol pretreatment of ABCA1-expressing fibroblasts reduced efflux to serum by 26%." | 1.33 | Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. ( Collins, HL; Duong, M; Favari, E; Jin, W; Rothblat, GH; Zanotti, I, 2006) |
| "Hyperlipidemia may induce oxidative stress, which is important in the pathogenesis of atherosclerosis." | 1.33 | Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. ( Chang, WC; Tseng, YH; Wu, CH; Wu, KY; Yu, YM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (47.37) | 29.6817 |
| 2010's | 23 (40.35) | 24.3611 |
| 2020's | 7 (12.28) | 2.80 |
| Authors | Studies |
|---|---|
| Lapeyre, C | 1 |
| Delomenède, M | 2 |
| Bedos-Belval, F | 2 |
| Duran, H | 2 |
| Nègre-Salvayre, A | 2 |
| Baltas, M | 2 |
| Park, KH | 1 |
| Park, YD | 1 |
| Han, JM | 1 |
| Im, KR | 1 |
| Lee, BW | 1 |
| Jeong, IY | 1 |
| Jeong, TS | 1 |
| Lee, WS | 1 |
| Rakotondramanana, DL | 1 |
| Rasoanaivo, P | 1 |
| Gornitzka, H | 1 |
| Matralis, AN | 4 |
| Katselou, MG | 2 |
| Nikitakis, A | 1 |
| Kourounakis, AP | 4 |
| Ladopoulou, E | 1 |
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Hoekstra, M | 2 |
| Van Eck, M | 2 |
| Okada, T | 1 |
| Sumida, M | 1 |
| Ohama, T | 1 |
| Katayama, Y | 1 |
| Saga, A | 1 |
| Inui, H | 1 |
| Kanno, K | 1 |
| Masuda, D | 4 |
| Koseki, M | 2 |
| Nishida, M | 1 |
| Sakata, Y | 1 |
| Yamashita, S | 4 |
| Zhang, S | 1 |
| Li, L | 1 |
| Chen, W | 1 |
| Xu, S | 1 |
| Feng, X | 1 |
| Zhang, L | 1 |
| Arai, H | 2 |
| Bujo, H | 2 |
| Ishibashi, T | 1 |
| Nakagawa, S | 1 |
| Tanabe, K | 1 |
| Kagimura, T | 1 |
| Kang, HJ | 1 |
| Kim, MH | 1 |
| Sung, J | 1 |
| Kim, SH | 1 |
| Kim, CH | 1 |
| Park, JE | 1 |
| Ge, J | 2 |
| Oh, BH | 1 |
| Kita, T | 1 |
| Saito, Y | 1 |
| Fukushima, M | 1 |
| Matsuzawa, Y | 1 |
| Chen, F | 1 |
| Chen, J | 1 |
| Han, C | 1 |
| Yang, Z | 1 |
| Deng, T | 1 |
| Zhao, Y | 1 |
| Zheng, T | 1 |
| Gan, X | 1 |
| Yu, C | 1 |
| Harada-Shiba, M | 1 |
| Ishibashi, S | 1 |
| Daida, H | 1 |
| Koga, N | 1 |
| Oikawa, S | 1 |
| Ahmad, F | 1 |
| Leake, DS | 1 |
| van der Sluis, RJ | 1 |
| Verwilligen, RAF | 1 |
| Lendvai, Z | 1 |
| Wever, R | 1 |
| Guo, X | 1 |
| Wang, L | 1 |
| Xia, X | 1 |
| Wang, P | 1 |
| Li, X | 4 |
| Xu, Y | 1 |
| Zhu, W | 1 |
| Wang, T | 1 |
| Jin, L | 1 |
| Liu, T | 1 |
| Guan, Z | 1 |
| Jiang, Z | 1 |
| Meng, X | 1 |
| Wang, J | 1 |
| Guo, Y | 2 |
| Chen, Y | 3 |
| Zhao, S | 3 |
| Huang, B | 1 |
| Wang, Y | 3 |
| Li, Y | 3 |
| Waqar, AB | 1 |
| Liu, R | 1 |
| Bai, L | 3 |
| Fan, J | 4 |
| Liu, E | 3 |
| Niimi, M | 2 |
| Keyamura, Y | 2 |
| Nozako, M | 3 |
| Koyama, T | 2 |
| Kohashi, M | 2 |
| Yasufuku, R | 2 |
| Yoshikawa, T | 3 |
| Li, JF | 1 |
| Chen, S | 1 |
| Feng, JD | 1 |
| Zhang, MY | 1 |
| Liu, XX | 1 |
| Nagano, C | 1 |
| Imaizumi, A | 1 |
| Itabe, H | 1 |
| Lin, Y | 2 |
| Guan, H | 2 |
| Zhu, N | 2 |
| Gao, S | 2 |
| Chen, Z | 1 |
| Li, S | 1 |
| Zhao, W | 1 |
| Chen, X | 1 |
| Wang, X | 1 |
| Zhu, H | 1 |
| Jin, X | 2 |
| Zhao, J | 1 |
| Dong, Z | 1 |
| Ma, X | 1 |
| Xu, F | 1 |
| Huang, W | 1 |
| Liu, G | 1 |
| Zou, Y | 1 |
| Wang, K | 1 |
| Hu, K | 1 |
| Sun, A | 1 |
| Freeman, SR | 1 |
| Vaisman, B | 1 |
| Liu, Y | 1 |
| Chang, J | 1 |
| Varsano, N | 1 |
| Addadi, L | 1 |
| Remaley, A | 1 |
| Kruth, HS | 1 |
| Sun, L | 1 |
| Yakushiji, E | 1 |
| Ayaori, M | 1 |
| Nishida, T | 1 |
| Shiotani, K | 1 |
| Takiguchi, S | 1 |
| Nakaya, K | 1 |
| Uto-Kondo, H | 1 |
| Ogura, M | 1 |
| Sasaki, M | 1 |
| Yogo, M | 1 |
| Komatsu, T | 1 |
| Lu, R | 2 |
| Yokoyama, S | 2 |
| Ikewaki, K | 1 |
| Yamamoto, A | 1 |
| Stocker, R | 6 |
| Xu, Z | 1 |
| Azordegan, N | 1 |
| Zhao, Z | 1 |
| Le, K | 1 |
| Othman, RA | 1 |
| Moghadasian, MH | 2 |
| Arakawa, R | 1 |
| Tsujita, M | 1 |
| Iwamoto, N | 1 |
| Ito-Ohsumi, C | 1 |
| Wu, CA | 1 |
| Shimizu, K | 1 |
| Aotsuka, T | 1 |
| Kanazawa, H | 1 |
| Abe-Dohmae, S | 1 |
| Meng, XP | 1 |
| Wang, SX | 1 |
| Zhang, JC | 1 |
| Li, ZX | 1 |
| Geng, L | 1 |
| Yin, CY | 1 |
| Inazu, A | 1 |
| Li, TT | 1 |
| Xie, Y | 1 |
| Tian, HB | 1 |
| Zhang, JN | 1 |
| Peng, J | 1 |
| Zhang, Y | 1 |
| Yamamoto, S | 1 |
| Tanigawa, H | 1 |
| Komaru, Y | 1 |
| Billheimer, JT | 1 |
| Rader, DJ | 1 |
| Zhong, JK | 1 |
| Guo, ZG | 1 |
| Li, C | 2 |
| Wang, ZK | 1 |
| Lai, WY | 1 |
| Tu, Y | 1 |
| Lan, XH | 1 |
| Zhou, YG | 1 |
| Xu, R | 1 |
| Chang, WC | 2 |
| Yu, YM | 2 |
| Wu, CH | 2 |
| Tseng, YH | 1 |
| Wu, KY | 1 |
| Choy, K | 3 |
| Beck, K | 3 |
| Png, FY | 1 |
| Wu, BJ | 3 |
| Leichtweis, SB | 1 |
| Thomas, SR | 1 |
| Hou, JY | 2 |
| Croft, KD | 2 |
| Mori, TA | 2 |
| Chiang, SY | 1 |
| Hirano, K | 1 |
| Ikegami, C | 1 |
| Tsujii, K | 1 |
| Zhang, Z | 1 |
| Matsuura, F | 1 |
| Nakagawa-Toyama, Y | 1 |
| Maruyama, T | 1 |
| Shimomura, I | 1 |
| Ueda, Y | 1 |
| Duong, M | 1 |
| Collins, HL | 1 |
| Jin, W | 1 |
| Zanotti, I | 1 |
| Favari, E | 1 |
| Rothblat, GH | 1 |
| Tardif, JC | 1 |
| Cynshi, O | 1 |
| Kathir, K | 1 |
| Witting, PK | 1 |
| Tanous, D | 2 |
| Adams, MR | 1 |
| Lau, AK | 1 |
| Sawayama, Y | 1 |
| Maeda, S | 1 |
| Ohnishi, H | 1 |
| Okada, K | 1 |
| Hayashi, J | 1 |
| Siekmeier, R | 1 |
| Steffen, C | 1 |
| März, W | 1 |
| Di Girolamo, N | 1 |
| Hanratty, CG | 1 |
| Ward, MR | 1 |
| Preiss, DJ | 1 |
| Sattar, N | 1 |
| Serebruany, VL | 1 |
| Malinin, A | 1 |
| Eisert, C | 1 |
| Ong, S | 1 |
| Yang, YB | 1 |
| Yang, YX | 1 |
| Su, B | 1 |
| Tang, YL | 1 |
| Zhu, BY | 1 |
| Hu, ZW | 1 |
| Li, GY | 1 |
| Li, YJ | 1 |
| Liao, DF | 1 |
| Van Antwerpen, P | 1 |
| Néve, J | 1 |
| Moreau, P | 1 |
| Boudjeltia, KZ | 1 |
| Vanhaeverbeek, M | 1 |
| Prévost, M | 1 |
| Babar, S | 1 |
| Legssyer, I | 1 |
| Moguilevsky, N | 1 |
| Ducobu, J | 1 |
| Wu, TC | 1 |
| Chen, YH | 1 |
| Leu, HB | 1 |
| Chen, YL | 1 |
| Lin, FY | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| Hime, N | 1 |
| Mitani, K | 1 |
| Kotosai, K | 1 |
| Miyakoda, G | 1 |
| Yabuuchi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for probucol and Atherogenesis
| Article | Year |
|---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis.
Topics: Abietanes; Antioxidants; Atherosclerosis; Biological Products; Catechin; Dietary Supplements; Humans | 2021 |
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Probucol | 2009 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Es | 2011 |
Antioxidants: the good, the bad and the ugly.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidativ | 2006 |
Inhibition of lipoprotein lipid oxidation.
Topics: Animals; Antioxidants; Atherosclerosis; Benzofurans; Cardiovascular Diseases; Humans; Lipoproteins, | 2005 |
[Can antioxidants prevent atherosclerosis?].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Anticholesteremic Agents; Antioxidants; Ascorb | 2006 |
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
Topics: Antioxidants; Atherosclerosis; Endothelium, Vascular; Evidence-Based Medicine; Gene Expression Regul | 2007 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosi | 2007 |
Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglyc | 2008 |
3 trials available for probucol and Atherogenesis
| Article | Year |
|---|---|
Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT.
Topics: Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Coronary Artery Disease; | 2022 |
[Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis].
Topics: Aged; Aspirin; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Female; H | 2009 |
Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascul | 2006 |
44 other studies available for probucol and Atherogenesis
| Article | Year |
|---|---|
Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents.
Topics: Antioxidants; Atherosclerosis; Cell Line; Cell Survival; Cinnamates; Cytoprotection; Drug Design; En | 2005 |
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Catechols; Cell Line; Flavonoids; Humans; Mice; | 2006 |
Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents.
Topics: Animals; Antioxidants; Atherosclerosis; Cell Survival; Coumaric Acids; Dimerization; Endothelium, Va | 2007 |
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
Topics: Animals; Antioxidants; Atherosclerosis; Benzoxazines; Cholesterol, LDL; Farnesyl-Diphosphate Farnesy | 2011 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Biphenyl Compounds; | 2014 |
Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
Topics: Animals; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Disease Mod | 2017 |
Probucol-induced hypocholesterolemia is not associated with exacerbated foam cell formation in ABCG1 knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 1 | 2020 |
Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Topics: Adult; Antioxidants; Atherosclerosis; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Huma | 2021 |
Theranostics of atherosclerosis by the indole molecule-templated self-assembly of probucol nanoparticles.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Cells, Cultured; Humans; Indocyan | 2021 |
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxy | 2022 |
Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed.
Topics: Animals; Antioxidants; Atherosclerosis; Cell Line; Ceroid; Chromatography, High Pressure Liquid; Cys | 2018 |
HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bone Marrow; Bone Marrow Transplantation; Cholesterol, | 2018 |
Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol; Cytokines; Die | 2019 |
Low molecule weight fucoidan mitigates atherosclerosis in ApoE (-/-) mouse model through activating multiple signal pathway.
Topics: Animals; Anticoagulants; Antioxidants; Apolipoproteins E; Atherosclerosis; Base Sequence; Cell Movem | 2019 |
Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Cholesterol, Dietary; Cilostazol; Drug Th | 2013 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; | 2013 |
Probucol via inhibition of NHE1 attenuates LPS-accelerated atherosclerosis and promotes plaque stability in vivo.
Topics: Animals; Atherosclerosis; Calcium; Calpain; Cation Transport Proteins; Humans; Lipopolysaccharides; | 2014 |
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Biomarkers; C-Reacti | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combinat | 2014 |
Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats.
Topics: Animals; Antioxidants; Atherosclerosis; Drug Therapy, Combination; Fluorobenzenes; Lipids; Male; Oxi | 2014 |
Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice.
Topics: Animals; Aortic Diseases; Atherosclerosis; Biomarkers; CD11c Antigen; Cells, Cultured; Cholesterol; | 2015 |
ABCA1 contributes to macrophage deposition of extracellular cholesterol.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Casset | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy | 2015 |
Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
Topics: Androstadienes; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Apoli | 2016 |
A uniqe antilipidemic drug--probucol.
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Bile Acids and Salts; Cell Line; Cholestero | 2008 |
Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cholesterol; Cytokines; Gene Expression Profilin | 2009 |
Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; ATP Binding Ca | 2009 |
Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study.
Topics: Animals; Anticholesteremic Agents; Aorta; Apoptosis; Atherosclerosis; Lipids; Macrophages; Male; Mat | 2011 |
Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding | 2011 |
Probucol alleviates atherosclerosis and improves high density lipoprotein function.
Topics: Animals; Anticholesteremic Agents; Aorta; Aryldialkylphosphatase; Atherosclerosis; ATP Binding Casse | 2011 |
[Effects of three different treatments on atherosclerosis and adipose in rats].
Topics: Adipose Tissue; Animals; Aspirin; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, | 2012 |
Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Atherosclerosis; Catalase; Dietary | 2005 |
Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis | 2005 |
Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Apopt | 2005 |
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Topics: Adult; Animals; Anticholesteremic Agents; Atherosclerosis; Carcinoma, Hepatocellular; Cell Line, Tum | 2005 |
Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cho | 2006 |
Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; A | 2006 |
Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Coronary Restenosis; Diabetes Mellitus, Type 2; Free Ra | 2006 |
Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Carotid Arteries; Male; Matri | 2007 |
Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
Topics: Angioplasty, Balloon; Animals; Antioxidants; Atherosclerosis; Caveolin 1; Cell Movement; Cell Prolif | 2007 |
Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Chlorides; Enzyme-Linked Immunosorbent Assay; Humans; Hyd | 2007 |
Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Aorta, Abdominal; Atherosclerosis; Carbazoles; C | 2007 |
Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cilostaz | 2008 |